The Molecular Imaging & Therapy Fellowship at Hoag offers competitive salary and benefits packages.
For full details please visit www.hoag.org/GME and navigate to the salary and benefits page.
Required Education:
Doctorate
Recruiting for start dates: July 1, 2025 & July 1, 2026
For full program description visit: www.hoag.org/MITFellowship
Goals & Objectives
Fellows in the Hoag Molecular Imaging and Therapy Program receive comprehensive clinical experience in molecular imaging and therapy, play a significant role in diagnostic consultation and are actively involved in regular triage of patients to ensure that the appropriate study is performed.
Faculty members are firmly committed to extensive elbow-to-elbow education in the reading room and Molecular Imaging and Therapy clinic and work collaboratively with a team of physicians, nurses, nuclear technologists and physicists.
Graduates of the program will gain expertise of molecular imaging and therapy through experience with > 1,500 PET/CT and PET/MR examinations and administration of > 300 radionuclide therapies. Fellows will also master clinical trial execution, including the completion, presentation, and publication of a mentored investigation.
Upon completion of the program, the Fellow will be eligible for both the American Board of Nuclear Medicine and the American Board of Radiology-Nuclear Radiology certifying exams. It is expected the Fellow will far exceed the requirements for these exams. Graduates of the program will be well poised to obtain an academic or community position as a Radiologist and/or Molecular Imaging and Therapy specialist.
Curriculum
This one (1) year program will provide a broad clinical experience in all aspects of molecular imaging and therapy, including:
FDA-approved PET radiotracers (FDG, 68Ga-Dotatate, 64Cu-Dotatate, Pylarify, Cerianna, Axumin)
Investigational PET radiotracers (targeting PSMA, ER, FAP, CD8, CD38, Amyloid, Tau, and others)
Investigational radionuclide therapies (targeting PSMA, FAP, SSTR, and others, including 225Ac alpha therapies)
PET/CT and PET/MR
General nuclear medicine
Basic principles of radiotracers, radiopharmacy, and radiation safety.
The program director ensures rotation responsibilities do not detract from a fellow’s overall educational experience. The allocation of fellowship time will be scheduled in advance and in collaboration with the fellow.
40% Clinical service for PET/CT, PET/MR
40% Clinical service in the Molecular Imaging & Therapy clinic
20% Clinical investigation. Each fellow will be mentored on an original research project with the goal of national/international presentation and publication.
Candidate Qualifications
Applicants must have completed a nuclear medicine or diagnostic radiology residency at an ACMGE accredited program and be either board-eligible or board-certified by the American Board of Nuclear Medicine or The American Board of Radiology.
Applicants must be eligible to obtain an unrestricted California medical license prior to the beginning of the Fellowship. We are unable to provide visa sponsorship at this time.
**Candidates who wish to start on July 1, 2025 must have a current California Medical License
**A current California Medical License is not required for a start date of July 1, 2026.
